Royalty Pharma plc reported $2.54B of revenue over the trailing twelve months, +10% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.54B (to Q2 2026). Net income: $815M, trailing twelve months to Q2 2026. Operating margin: 60%, trailing twelve months to Q2 2026. EPS: $1.88, trailing twelve months to Q2 2026.

RPRXRoyalty Pharma plc

Healthcare

$56.90+59% 1Y

$56.90

$34.3752 weeks$63.98

RPRX as reported

Royalty Pharma plc reported $2.54B of revenue over the trailing twelve months, +10% on the year before. 9 reported series are charted on this page, each one as filed.

$2.54B

Revenue, trailing twelve months · to Q2 2026 · +10% against the twelve months before

Net income: $815M
Net income · −20% year on year · trailing twelve months to Q2 2026
Operating margin: 60%
Operating margin · trailing twelve months to Q2 2026
EPS: $1.88
EPS · −18% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RPRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.54B	+10%	Q2 2026
Net income	$815M	−20%	Q2 2026
EPS	$1.88	−18%	Q2 2026
Operating margin	60%	n/a	Q2 2026
Net margin	33%	n/a	Q2 2026
ROE	8.2%	n/a	Q2 2026
ROA	4.1%	n/a	Q2 2026
ROIC	6.8%	n/a	Q2 2026
P/E	30.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.